1.
Andlovic A, Babic M, Accetto S, Rot U: Comparison of two methods for the detection of oligoclonal bands in a large number
of clinically isolated syndrome and multiple sclerosis patients. Clin Neurol Neurosurg 2012, 114(6):659-662.
2.
Davies G, Keir G, Thompson EJ, Giovannoni G: The clinical significance of an intrathecal monoclonal immunoglobulin band: a follow-up
study. Neurology 2003, 60(7):1163-1166.
3.
Villar LM, Masterman T, Casanova B, Gomez-Rial J, Espino M, Sadaba MC, Gonzalez-Porque
P, Coret F, Alvarez-Cermeno JC: CSF oligoclonal band patterns reveal disease heterogeneity in multiple sclerosis. Journal of neuroimmunology 2009, 211(1-2):101-104.
4.
Link H, Huang YM: Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology
and clinical usefulness. Journal of neuroimmunology 2006, 180(1-2):17-28.
5.
Abraira V, Alvarez-Cermeno JC, Arroyo R, Camara C, Casanova B, Cubillo S, de Andres
C, Espejo C, Fernandez O, Ferrer J et al: Utility of oligoclonal IgG band detection for MS diagnosis in daily clinical practice. J Immunol Methods 2011, 371(1-2):170-173.
6.
Lechner-Scott J, Spencer B, de Malmanche T, Attia J, Fitzgerald M, Trojano M, Grand'Maison
F, Gomez JA, Izquierdo G, Duquette P et al: The frequency of CSF oligoclonal banding in multiple sclerosis increases with latitude. Mult Scler 2012, 18(7):974-982.
7.
Masjuan J, Alvarez-Cermeno JC, Garcia-Barragan N, Diaz-Sanchez M, Espino M, Sadaba
MC, Gonzalez-Porque P, Martinez San Millan J, Villar LM: Clinically isolated syndromes: a new oligoclonal band test accurately predicts conversion
to MS. Neurology 2006, 66(4):576-578.
8.
Andersson M, Alvarez-Cermeno J, Bernardi G, Cogato I, Fredman P, Frederiksen J, Fredrikson
S, Gallo P, Grimaldi LM, Gronning M et al: Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report. J Neurol Neurosurg Psychiatry 1994, 57(8):897-902.
9.
von Glehn F, Farias AS, de Oliveira AC, Damasceno A, Longhini AL, Oliveira EC, Damasceno
BP, Santos LM, Brandao CO: Disappearance of cerebrospinal fluid oligoclonal bands after natalizumab treatment
of multiple sclerosis patients. Mult Scler 2012, 18(7):1038-1041.
10.
Chen Y: Multiple cerebrospinal fluid bands with accompanying serum bands. Clin Chem 2014, 60(12):1582-1583.
11.
Petzold A: Intrathecal oligoclonal IgG synthesis in multiple sclerosis. Journal of neuroimmunology 2013, 262(1-2):1-10.
12.
Freedman MS, Thompson EJ, Deisenhammer F, Giovannoni G, Grimsley G, Keir G, Ohman
S, Racke MK, Sharief M, Sindic CJ et al: Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple
sclerosis: a consensus statement. Arch Neurol 2005, 62(6):865-870.
13.
Chen Y, Watts G: Systemic inflammation or monoclonal gammopathy? Arch Pathol Lab Med 2011, 135(12):1527-1529.
14.
Franciotta D, Zardini E, Lolli F: The clinical significance of an intrathecal monoclonal immunoglobulin band: a follow-up
study. Neurology 2004, 62(4):675; author reply 675-676.
15.
Reiber H, Thompson EJ, Grimsley G, Bernardi G, Adam P, Monteiro de Almeida S, Fredman
P, Keir G, Lammers M, Liblau R et al: Quality assurance for cerebrospinal fluid protein analysis: international consensus
by an Internet-based group discussion. Clin Chem Lab Med 2003, 41(3):331-337.
16.
Wu Y, Yang X, Wang T, Wang H, Li Z: Identification of M protein from filter paper using serum protein and immunofixation
electrophoresis. Am J Clin Pathol 2012, 138(4):604-608.
17.
Haertle M, Kallweit U, Weller M, Linnebank M: The presence of oligoclonal IgG bands in human CSF during the course of neurological
diseases. J Neurol 2014, 261(3):554-560.
18.
Reiber H, Peter JB: Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs. J Neurol Sci 2001, 184(2):101-122.
19.
Reiber H: Cerebrospinal fluid--physiology, analysis and interpretation of protein patterns for
diagnosis of neurological diseases. Mult Scler 1998, 4(3):99-107.
20.
McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty
DW, Polman CH, Reingold SC et al: Recommended diagnostic criteria for multiple sclerosis: guidelines from the International
Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001, 50(1):121-127.
21.
Blennow K, Fredman P, Wallin A, Gottfries CG, Karlsson I, Langstrom G, Skoog I, Svennerholm
L, Wikkelso C: Protein analysis in cerebrospinal fluid. II. Reference values derived from healthy
individuals 18-88 years of age. Eur Neurol 1993, 33(2):129-133.
22.
Sadaba MC, Gonzalez Porque P, Masjuan J, Alvarez-Cermeno JC, Bootello A, Villar LM:
An ultrasensitive method for the detection of oligoclonal IgG bands. J Immunol Methods 2004, 284(1-2):141-145.
23.
Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova
E, Hutchinson M, Kappos L et al: Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011, 69(2):292-302.
24.
Chen Y: Laboratory Performance on Reporting Monoclonal Gammopathy During Cerebrospinal Fluid
Oligoclonal Banding Analysis from External Quality Assessment Surveys. the Journal of APPLIED LABORATORY MEDICINE 2018, 3(2):261-266.
25.
Go RS, Swanson KM, Sangaralingham LR, Habermann EB, Shah ND: Clinical prevalence (diagnosed cases) of monoclonal gammopathy of undetermined significance
in the US: estimating the burden on health care. Leukemia 2016, 30(6):1443-1446.
26.
Willrich MAV, Murray DL, Kyle RA: Laboratory testing for monoclonal gammopathies: Focus on monoclonal gammopathy of
undetermined significance and smoldering multiple myeloma. Clin Biochem 2018, 51:38-47.
27.
Chaudhry HM, Mauermann ML, Rajkumar SV: Monoclonal Gammopathy-Associated Peripheral Neuropathy: Diagnosis and Management. Mayo Clin Proc 2017, 92(5):838-850.
28.
Dhodapkar MV: MGUS to myeloma: a mysterious gammopathy of underexplored significance. Blood 2016, 128(23):2599-2606.